




Neuroprotective Strategies in Neurodegenerative Diseases Group

Publications: 8

Impact Factor: 107,781

Q1: 6



Research Activity

Doctoral theses

Robledinos Antón N. Orchestration of the neural stem cell fate by NRF2 and TAZ [dissertation]. Madrid: UAM: 2019(11/10/2019).

Director: Cuadrado Pastor A

Publications

- Castro-Sánchez S, García-Yagüe AJ, Kugler S, Lastres-Becker I. CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies. *Redox Biol.* 2019; 22: 101118. Article. IF: 9.986; D1
- Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousins SP, Rumsey WL, Attucks OC, Franklin S, Levenon AL, Kensler TW, Dinkova-Kostova AT. Therapeutic

targeting of the NRF2 and KEAP 1 partnership in chronic diseases. *Nat Rev Drug Discov.* 2019; 18(4): 295-317. Review. IF: 64.797; D1

- Elbatreek MH, Pachado MP, Cuadrado A, Jandeleit-Dahm K, Schmidt HHHW. Reactive oxygen comes of age: Mechanism-based therapy of diabetic end-organ damage. *Trends Endocrin Met.* 2019; 30(5): 312-27. Review. IF: 11.641; D1
- Galán-Ganga M, García-Yague AJ, Lastres-Becker I. Role of MSK1 in the induction of NF-B by the chemokine CX3CL1 in microglial cells. *Cell Mol Neurobiol.* 2019; 39(3): 331-40. Article. IF: 3.606; Q2
- Martín-Hurtado A, Martín-Morales R, Robledinos-Antón N, Blanco R, Palacios-Blanco I, Lastres-Becker I, Cuadrado A, García-Gonzalo FR. NRF2-dependent gene expression promotes ciliogenesis and Hedgehog signaling. *Sci Rep-Uk.* 2019; 9: 13896.

Article. IF: 3.998; Q1

- Rada P, Mosquera A, Muntane J, Ferrandiz F, Rodríguez-Manas L, de Pablo F, Gonzalez-Canudas J, Valverde AM. Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice. *Food Chem Toxicol.* 2019; 123: 470-80. Article. IF: 4.679; Q1
- Rius-Pérez S, Tormos AM, Pérez S, Finamor I, Rada P, Valverde AM, Nebreda AR, Sastre J, Talens-Visconti R. P38 alpha deficiency restrains liver regeneration after partial hepatectomy triggering oxidative stress and liver injury. *Sci Rep-Uk.* 2019; 9: 3775. Article. IF: 3.998; Q1
- Robledinos-Antón N, Fernández-Gines R, Manda G, Cuadrado A. Activators and Inhibitors of NRF2:

A review of their potential for clinical development. *Oxid Med Cell Longev.* 2019; 2019: 9372182. Review. IF: 5.076; Q2

Research projects

Cuadrado Pastor A. Papel de NRF2 en la función y el destino del cerebro con Alzheimer (SAF2016-76520-R). MICINN. 2017-2019.

Management centre: UAM

Cuadrado Pastor A. Advanced theranostic approach in cancer combining photodynamic therapy and nanoparticles (PCIN-2016-071). MICINN/ M.ERANET. 2016-2019.

Management centre: UAM



Martínez Valverde A. Mecanismos moleculares y comunicación intertisular en la resistencia a la insulina (B2017/BMD-3684 MOIR2-CM). CAM. 2018-2020.

Management centre: CISC

Martínez Valverde A. Experimental designs for studies on the role of g49 in dietinduced obesity (dio) in mice and human cells: impact on inflammation and mitochondria. Astrazeneca. 2018-2019.

Management centre: CISC

Cibers and Retics

Cuadrado Pastor A. Networked Biomedical Research Center for Neurodegenerative Diseases. (CIBERNed). ISCIII. (31/12/2019).

Management centre: UAM.

Cuadrado Pastor A. Research Network NRF2 as a Node of the Pathogenesome [SAF2015-71304-REDT]. Ministerio de Ciencia, Innovación y Universidades. (31/12/2019).

Management centre: UAM

Patents and trademarks

Cuadrado Pastor A. Innamorato NG, inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la

Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-[2-isothiocyanatoethyl]-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October 15.